Icon times
Q4FY21 and FY21 result analysis of Biocon

Q4FY21 and FY21 Result Analysis of Biocon

Published on 04 May 2021|
Share -

Revenue

  • Biosimilars segment reported revenue to the extent of Rs. 664 crores as against Rs. 433 crores during the same period last year, a jump of about 53% YoY.
  • Generics reported a jump of 2.8% YoY and 3% QoQ in revenue.
  • Overall revenue jumped 12.8% to Rs.7106 crores in FY21 as against Rs.6301 crores in FY20.

 

EBITDA

  • Q4 FY21 EBITDA stands at 436 crores, up 9.3% QoQ and 37.1% YoY.
  • Improvement in EBITDA margins on account of higher operational efficiencies. Q4 FY21 margins were up by 330 bps YoY and 220 bps QoQ.

 

As per the latest quarterly report, investment in Bicara Therapeutics was reclassified as an associate investment from subsidiary investment. This resulted in a one-time gain of 160 crores for Biocon Limited and the same has been reported under other income section of the Income Statement. Generics business saw a mild jump in revenue numbers on account of pricing pressure on both API’s and formulations, travel bans causing delay in regulatory approvals and new product launch. Syngene crossed milestone on account of collaboration extension with Bristol Myers Squibb till 2030. The agreement includes drug discovery research, 40% increase in the number of scientists and an additional 50,000 sq. ft. of laboratory space. 

Detailed Q4FY21 and FY21 Results analysis

Attachments
File Name
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs 7499/Year.

LATEST UPDATE

premium Premium
free Free
Read More

REPORTS


Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya